Jianyou Co., Ltd.: Subsidiary receives FDA approval for the transfer of registration for the production site of Famotidine injection in the United States

2026-03-19 03:08:57

Jianyou Co., Ltd. announced that its subsidiary, Hong Kong Jianyou, has received approval for the transfer of manufacturing site for Lefamulin Injection, 150mg/15mL (NDA No.: 211673), to Jianjin Pharmaceutical Co., Ltd. Lefamulin Injection, as an innovative drug, was approved by the U.S. FDA for marketing on August 19, 2019, under the brand name XENLETA. According to inquiries, there are currently no generic versions approved for marketing in the United States.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes